The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
hypertension
dyslipidemia
obstructive sleep apnea
Fatty liver
Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
Have a self-reported change in body weight >5 kg within 90 days prior to screening
Had chronic or acute pancreatitis any time prior to screening
Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome
Parallel
Orforglipron
DrugAdministered orally.
Placebo
DrugAdministered orally.
Mean Percent Change From Baseline in Body Weight
Mean Change from Baseline in Waist Circumference
Mean Change from Baseline in Body Mass Index (BMI)
Mean Change from Baseline in Hemoglobin A1c (HbA1c)
Mean Change from Baseline in Fasting Glucose
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
